These TCSP-based biomarkers predicted response to anti-PD-1 therapies in HNSCC, NSCLC, and Melanoma, and out-performed the on label PD-L1 test and Tumor Mutational Burden (TMB). This evidence concerns the gene PDCD1 and melanoma.